Market Capitalization (Millions $) |
39 |
Shares
Outstanding (Millions) |
11 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-34 |
Cash Flow (TTM) (Millions $) |
-15 |
Capital Exp. (TTM) (Millions $) |
1 |
Neoleukin Therapeutics Inc
Neoleukin Therapeutics Inc is a biopharmaceutical company specializing in the development of immunotherapies for the treatment of various diseases. The company focuses on engineering synthetic proteins that can activate the immune system or mimic natural proteins to regulate it.
Using a proprietary computational platform, Neoleukin designs and develops novel protein therapeutics with improved properties and capabilities compared to existing treatments. These therapeutic candidates are being developed to target a range of diseases, including autoimmune disorders, cancer, and metabolic diseases.
Neoleukin's approach involves modifying the structure of proteins to enhance their potency, stability, and selectivity, allowing for more effective and precise treatments. By harnessing the body's natural defense mechanisms, the company aims to provide safer and more targeted therapies with fewer side effects.
The company is committed to advancing scientific research and collaborating with other experts in the field to accelerate the development of innovative therapies. Neoleukin Therapeutics Inc is at the forefront of the biopharmaceutical industry, striving to make a significant impact in the field of immunotherapy for the benefit of patients worldwide.
Company Address: 188 East Blaine Street Seattle 98102 WA
Company Phone Number: 245-0312 Stock Exchange / Ticker: NASDAQ NLTX
|